Literature DB >> 14734611

Role of L-selectin in the development of autoimmune diabetes in non-obese diabetic mice.

Conchi Mora1, Iqbal S Grewal, F Susan Wong, Richard A Flavell.   

Abstract

Autoimmune diabetes is characterized by an early mononuclear infiltration of pancreatic islets and later selective autoimmune destruction of insulin-producing beta cells. Lymphocyte homing receptors have been considered candidate targets to prevent autoimmune diabetes. L-selectin (CD62L) is an adhesion molecule highly expressed in naive T and B cells. It has been reported that blocking L-selectin in vivo with a specific antibody (Mel-14) partially impairs insulitis and diabetes in autoimmune diabetes-prone non-obese diabetic (NOD) mice. In the present study we aimed to elucidate whether genetic blockade of leukocyte homing into peripheral lymph nodes would prevent the development of diabetes. We backcrossed L-selectin-deficient mice onto the NOD genetic background. Surprisingly NOD/L-selectin-deficient mice exhibited unaltered islet mononuclear infiltration, timing of diabetes onset and cumulative incidence of spontaneous diabetes when compared to L-selectin-sufficient animals. CD4, CD8 T cells and B cells were present in islet infiltrates from 9-week-old L-selectin-sufficient and -deficient littermates. Moreover, total splenocytes from wild-type, heterozygous or NOD/L-selectin-deficient donor mice showed similar capability to adoptively transfer diabetes into NOD/SCID recipients. On the other hand, homing of activated, cloned insulin-specific autoaggressive CD8 T cells (TGNFC8 clone) is not affected in NOD/L-selectin-deficient recipients. We conclude that L-selectin plays a small role in the homing of autoreactive lymphocytes to regional (pancreatic) lymph nodes in NOD mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734611     DOI: 10.1093/intimm/dxh036

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

Review 1.  Immune cell trafficking to the islets during type 1 diabetes.

Authors:  A M Sandor; J Jacobelli; R S Friedman
Journal:  Clin Exp Immunol       Date:  2019-08-30       Impact factor: 4.330

2.  Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type I diabetes.

Authors:  Anja Jaeschke; Mercedes Rincón; Beth Doran; Judith Reilly; Donna Neuberg; Dale L Greiner; Leonard D Shultz; Aldo A Rossini; Richard A Flavell; Roger J Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-02       Impact factor: 11.205

3.  FoxP3+RORgammat+ T helper intermediates display suppressive function against autoimmune diabetes.

Authors:  Danielle M Tartar; Amie M VanMorlan; Xiaoxiao Wan; F Betul Guloglu; Renu Jain; Cara L Haymaker; Jason S Ellis; Christine M Hoeman; Jason A Cascio; Mermagya Dhakal; Mohamed Oukka; Habib Zaghouani
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

Review 4.  Sialic acids and autoimmune disease.

Authors:  Vinay S Mahajan; Shiv Pillai
Journal:  Immunol Rev       Date:  2016-01       Impact factor: 12.988

5.  Combined fish oil and astaxanthin supplementation modulates rat lymphocyte function.

Authors:  Rosemari Otton; Douglas Popp Marin; Anaysa Paola Bolin; Rita de Cássia Santos Macedo; Thais Regina Campoio; Claudio Fineto; Beatriz Alves Guerra; José Roberto Leite; Marcelo Paes Barros; Rita Mattei
Journal:  Eur J Nutr       Date:  2011-10-05       Impact factor: 5.614

6.  Anti-TCRβ mAb in Combination With Neurogenin3 Gene Therapy Reverses Established Overt Type 1 Diabetes in Female NOD Mice.

Authors:  Aini Xie; Rongying Li; Tao Jiang; Hui Yan; Hedong Zhang; Yisheng Yang; Lina Yang; Vijay Yechoor; Lawrence Chan; Wenhao Chen
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

7.  CD11c+ Cells Are Gatekeepers for Lymphocyte Trafficking to Infiltrated Islets During Type 1 Diabetes.

Authors:  Adam M Sandor; Robin S Lindsay; Nathan Dyjack; Jennifer C Whitesell; Cydney Rios; Brenda J Bradley; Kathryn Haskins; David V Serreze; Aron M Geurts; Yi-Guang Chen; Max A Seibold; Jordan Jacobelli; Rachel S Friedman
Journal:  Front Immunol       Date:  2019-01-31       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.